» Articles » PMID: 20658962

Therapeutic Targeting of MiRNAs in Neuroblastoma

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2010 Jul 28
PMID 20658962
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Importance Of The Field: Neuroblastomas arise from precursor cells of the sympathetic nervous system and are noted for highly heterogeneous clinical behavior. These tumors currently account for approximately 15% of all childhood cancer related deaths in spite of intensive multimodal chemotherapy and are a major problem in pediatric oncology. The identification of novel therapeutic targets is urgently required to reduce patient morbidity.

Areas Covered In This Review: The purpose of this article is to review and synthesize all of the rapidly expanding evidence for the contribution of microRNAs (miRNAs) in neuroblastoma aggressive disease pathogenesis, along with the prospect of using small RNAs as therapeutics.

What The Reader Will Gain: The reader will obtain insight on the miRNAs that are dysregulated in neuroblastoma along with potential therapeutic strategies and the most promising targets.

Take Home Message: A number of miRNAs which are associated with aggressive disease pathogenesis in neuroblastoma patients have been demonstrated to contribute in major ways to cell proliferation rates, apoptosis, differentiation, invasiveness and tumor growth in vitro and in vivo. Directly or indirectly interfering with the function of these miRNAs may prove to be an important and novel form of therapy.

Citing Articles

Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis.

Han M, Niu H, Duan F, Wang Z, Zhang Z, Ren H Front Oncol. 2024; 14:1383805.

PMID: 39450262 PMC: 11499224. DOI: 10.3389/fonc.2024.1383805.


Structural Insights on Tiny Peptide Nucleic Acid (PNA) Analogues of miRNA-34a: An and Experimental Integrated Approach.

Moccia M, Mercurio F, Langella E, Piacenti V, Leone M, Adamo M Front Chem. 2020; 8:568575.

PMID: 33330358 PMC: 7719796. DOI: 10.3389/fchem.2020.568575.


Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.

Coronado E, Yanez Y, Vidal E, Rubio L, Vera-Sempere F, Canada-Martinez A Mol Oncol. 2020; 15(2):364-380.

PMID: 33252831 PMC: 7858123. DOI: 10.1002/1878-0261.12868.


MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution.

Aravindan N, Subramanian K, Somasundaram D, Herman T, Aravindan S Cancer Drug Resist. 2019; 2:1086-1105.

PMID: 31867575 PMC: 6924638. DOI: 10.20517/cdr.2019.68.


A novel miR17/protein tyrosine phosphatase-oc/EphA4 regulatory axis of osteoclast activity.

Lau K, Sheng M Arch Biochem Biophys. 2018; 650:30-38.

PMID: 29763590 PMC: 5985224. DOI: 10.1016/j.abb.2018.05.014.